Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

NCT07257510 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)
POZ

Interventions

DRUG: Pomalidomide
DRUG: Orelabrutinib
DRUG: Zuberitamab
DRUG: Zuberitamab

Sponsor

Peking University Third Hospital